AAP
CAPR icon

Arax Advisory Partners’s Capricor Therapeutics CAPR Stock Holding History

Arax Advisory Partners’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.85K Buy
+409
New +$12.4K ﹤0.01% 4342
2025
Q4 		– Sell
-182
Closed -$1.31K – 4143
2025
Q3 		$1.31K Buy
+182
New +$1.34K ﹤0.01% 3196

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arax Advisory Partners's CAPR Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 409 shares worth $9.85K. The stake represents ﹤0.01% of the portfolio and ranks #4342 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CAPR as recently as Q3 2025.

Arax Advisory Partners first reported a position in CAPR in Q3 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Arax Advisory Partners held 409 shares of Capricor Therapeutics worth $9.85K as of Q2 2026.
  • Capricor Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4342 holding.
  • Arax Advisory Partners first reported a position in Capricor Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.